We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
MHRA announces new programme of events and greater engagement with industries, researchers, local NHS and government in Wales.
Innovation doesn’t wait for the rules to catch up. The question is whether we can build a system agile and flexible enough to keep pace.
As with any medicine, the MHRA will keep the safety and effectiveness of Vyjuvek under close review.
The MHRA hub in Belfast will strengthen collaboration and engagement with local industry, academia and the healthcare sector.
Updated safety advice has been issued to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride and to provide precautionary advice on dutasteride.
To future-proof the sector and ensure regulation keeps up with scientific and technological developments, the MHRA is consulting on proposed changes to how gene therapies are defined in UK legislation.
New pre-market regulatory requirements for medical devices and in vitro diagnostic devices entering the GB market have been published.
The MHRA continues to speed up access to medicines for patients, increase efficiency of regulation and help to attract innovation and investment in the UK’s thriving £100 billion life sciences industry.
MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema
MHRA and UK Border Force crack down on the illegal medicines trade in intensive 14-day international operation.
As with all medicines, we will continue to closely monitor the safety and effectiveness of linerixibat as it is used more widely.
The MHRA has limited the use of nasal decongestant sprays containing xylometazoline and oxymetazoline to a maximum of five days due to side effects of prolonged use.
The Medicines and Healthcare products Regulatory Agency (MHRA) is pleased to announce the appointment of Jason Bonander as its new Chief Digital and Technology Officer (CDTO).
An MHRA-led investigation has exposed a £1.8 million illegal medicines and steroids network, leading to seven men being sentenced.
The MHRA has advised healthcare professionals to stop supplying the affected batch of Sertraline 100mg and return all remaining stock to their suppliers.
Patients in the UK to get access to new treatments faster and still safely under new clinical trial regulations coming into force on 28 April 2026.
Specific batches of Napralief 250mg Gastro‑Resistant Tablets are being recalled because important safety and dosage information is missing from both the patient information leaflet and the outer carton.
As with any medicine, the MHRA will keep the safety and effectiveness of Enflonsia under close review.
The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.
By Dame Jennifer Dixon
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).